Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Fingolimod in Schizophrenia Patients Who Have Suboptimal Responses to Antipsychotic Drug Treatment

Trial Profile

Safety and Efficacy of Fingolimod in Schizophrenia Patients Who Have Suboptimal Responses to Antipsychotic Drug Treatment

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2019

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Adverse reactions; Proof of concept
  • Acronyms STEP
  • Most Recent Events

    • 25 Mar 2019 Status changed from active, no longer recruiting to completed.
    • 09 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
    • 30 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top